Slide 1: NEXGEL Investor Presentation August 2025
@) NEXGEL d hydrogel soluti Investor Presentatio August 2025 / / @NEXCEL NASDAQ: NXGL | iN A \
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Companys product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and o
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel Agreements with Multi-Billion solutions for large medical device companies, our Dollar Corporations business today includes the development of patented medical devices, custom/white label _—— products, and OTC healthcar
Slide 4: Multiple Products & Applications for Nexgel's Technology
Multiple Products & Applications for Nexgel’s Technology @NEXGEL Medical Device NEXGEL is addressing the importance of skin integrity and overall skincare with a medical device licensing model Custom & White Label Bringing proven medical-grade technology to OTC and Beauty & Cosmetics for the first t
Slide 5: Competitive Advantage: State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments 1 of 2 manufacturing facilities 16,500-square-
Slide 6: Converting and Packaging Facility
Converting and Packaging Facility 50% ownership in converting and packaging business in Granbury, Texas * Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts - Increased square footage and installed cutti
Slide 7: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications + Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 8: Current Medical Device Pipeline
Current Medical Device Pipeline Addressing the importance of skin integrity and \\ overall skincare with a medical device / A | \ | @NEXGEL NASDAQ: NXGL \ \ x /| |
Slide 9: Medical Device Pipeline: Drug Delivery
Medical Device Pipeline: Drug Delivery Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology Drug Delivery: Diclofenac Patch To treat short-term pain due to preclinical sprains and bruises Drug Delivery: Apremilast Patch copa alum fromNEXGEL Patch After Hours To treat
Slide 10: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications I \ NASDAQ: NXGL \ \ /
Slide 11: NEXGEL Branded Products
NEXGEL Branded Products eT NASDAQ: NXGL.
Slide 12: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand + Acquisition completed in December 2023 + Acquisition completed in May 2024 + Complimentary line of alternative psoriasis treatments * Specialty eye and eyelash consumer product line + Profitable (ttm) and im
Slide 13: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America * Cintas will distribute SilverSeal, NEXGEL’s hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 14: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with a leading European consumer health company accelerates the expansion of NEXGEL's OTC product portfolio * STADA, a global leader in consumer healthcare, generics, and specialty pharmaceuticals with sales in ~120 countries, is using this partnership to establish
Slide 15: AbbVie
AbbVie (NYSE: ABBV) CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie'’s Rapid Acoustic Pulse device for the improvement in the appearance of cellulite + Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for $550 m
Slide 16: New Partnerships & Customers
New Partnerships & Customers Reducing Carcinogenic Plume in Laser Hair Removal iRhythm’s (NASDAQ: IRTC) ECG Heart Monitor Supply iRhythm with our ultra-gentie. high-moisture hydrogel for integration into the Zio® ECG heart monitor. An FDA-compliant IRB study conducted by Innovative Optics evaluating
Slide 17: Revenue for Q2'25
Revenue for Q2’25 $3.04M $2.94 $3,000 stasyor “SOY goa $2.88 : 121% YOY +100%YO¥ $2,500 $2,000 sian $1,900 gizmm —#23%6YOY stom, o#evOr 1110360 $1,000 TTM $500 Revenue $1.7M $80 Immifong 042022 -=« 1 2024-—=—«GR2K24 BONE AOS 20S @) « NASDAQ: NXGL Highlights: Q2 2025 Revenue: $2.88 million, +100% vs
Slide 18: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com NASDAQ: NXGL |